Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen CEO Joins Genomica s Board of Directors

NEW YORK, March 14 – Bioinformatics company Genomica said Wednesday it had appointed William Rich, CEO of Ciphergen Biosystems, to its board of directors, signaling the company’s growing interest in the field of proteomics.

"His experience in the industry in general and, in particular, the emerging field of protein-based biology research known as proteomics, will help us as we expand our product line and functionality," Teresa Ayers, CEO of Genomica, said in a statement.

Ciphergen of Fremont, Calif., was among the first companies to market protein chips to detect and validate proteins.

Ayers could not immediately be reached for comment regarding Genomica’s plans for the proteomics sector.

Genomica currently develops software that is designed to help researchers integrate and interpret genomics data culled from a variety of sources.

The company’s customers include AstraZeneca, GlaxoSmithKline and Aventis. Genomica of Boulder also has a deal to develop software that can be integrated with Applied Biosystems’ hardware.

 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.